Human study PLS-00182

Identification of tubulin beta chain, thymosin beta-4-like protein 3, and cytochrome b-c₁ complex subunit 1 as serological diagnostic biomarkers of gastric cancer.

Case-control study · Not reported participants enrolled · not included in the assessments (wrong compound)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

Identification of tubulin beta chain, thymosin beta-4-like protein 3, and cytochrome b-c₁ complex subunit 1 as serological diagnostic biomarkers of gastric cancer.primary · Clinical biochemistry · 2013-06-06 · PMID 23747515 · DOI

Design and participants

Design: Case-control study
Population: Gastric cancer patients and healthy volunteers who provided serum for proteomic profiling
Conditions: Gastric cancer
Planned enrollment (registry): Not reported
Enrolled: Not reported
Randomized: Not reported
Completed follow-up: Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

The authors concluded (paraphrased): A four-peak serum protein/peptide pattern showed great potential for diagnosing gastric cancer. Tubulin beta chain, thymosin beta-4-like protein 3 and cytochrome b-c1 complex subunit 1 may be involved in its pathogenesis and could serve as serological biomarkers.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

other: Thymosin beta-4 was not administered. A related endogenous protein was measured only as a diagnostic biomarker.
abstract only: Only the abstract is available. Sample sizes, setting and funding are not reported in the record.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Improves dry eye signs and symptoms: not eligible (not primary study) for “Ocular discomfort and corneal staining”
Is safe for human administration: not eligible (not primary study) for “Adverse events, serious adverse events and discontinuations”

Where each value comes from

author_conclusion: PMID 23747515, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
design: PMID 23747515, abstract (Design and methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
population: PMID 23747515, abstract (Design and methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).